Tagged as: ustekinumab-stba

FDA Approves Celltrion’s New Pediatric Formulation of STEQEYMA, Expanding Dosing Flexibility

On June 15, 2025, Celltrion announced that the FDA has approved a new 45mg/0.5mL single-dose vial presentation of STEQEYMA (ustekinumab-stba) for subcutaneous injection.  The formulation is intended for pediatric patients (ages 6–17) under 60kg with plaque psoriasis (PsO) or psoriatic arthritis (PsA).  With this approval, STEQEYMA now matches all dosage…

Read More

Celltrion Wins Costco Formulary Listing for its Recently Launched Ustekinumab

Last week, we reported Celltrion’s U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab).  According to Celltrion, STEQEYMA® is being sold at a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA®.  This week, Celltrion announced that STEQEYMA® will…

Read More